A detailed characterisation of drug resistance during darunavir/ritonavir (DRV/r) monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance
A. Abdullahi, A. G. Diaz, O. M. Fopoussi, A. Beloukas, V. F. Defo, J. Torimiro, A. M. Geretti
This study characterizes drug resistance during DRV/r monotherapy, finding no DRV resistance mutations but identifying alternative resistance pathways through gag substitutions.
bioRxiv · Oct 15, 2023 · PreprintMicrobiology